Silk'n HST for Wrinkle Reduction - Clinical Study Protocol

Wrinkles Clinical Trial

Official title:

Safety, Efficacy and Usage Compliance of the Silk'n HST Home Use Device for Treating Periorbital Wrinkles and Improving Skin Appearance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02913547
• Other study ID #: DO109828
• Status: Completed
• Phase: N/A
• Start date: November 2015
• Est. completion date: June 2016

Study information

• Verified date: September 2016
• Source: Home Skinovations Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the safety, efficacy and usage compliance of the home-use device Silk'n HST for self-treatment of periorbital wrinkles and skin laxity and improvement of skin appearance.

Description:

This is a single arm prospective study of 18 weeks aimed to evaluate the safety and efficiency of Silk'n HST treatment on the periorbital areas. 30 subjects will be enrolled by a single USA clinical site. Throughout the trial there will be 3 pre-scheduled face to face treatment visits, as well as additional 18 independent treatments at home. 2 additional follow-up visits will be conducted 1 and 3 months following treatment end. In addition, 2 maintenance treatment will be conducted independently at home once a month following treatment end.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adult subjects aged 35-65.

2. The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects, and sign the Informed Consent Form, including the permission to use photography (forms attached).

3. The subjects should be willing to comply with the study procedure and schedule, including the follow up visits, and will refrain from using any other or similar treatment technologies (i.e., Laser, RF, IR) for the facial condition.

4. The subjects will carry on with their usual diet and exercise and will not have a significant weight change during the study.

5. The subject is able to read the User Manual in English.

6. Subjects should have II-VI Fitzpatrick wrinkle score as indicated on the Fitzpatrick Wrinkle and Elastosis Scale (see Table 1).

7. Negative results in a urine pregnancy test.

Exclusion Criteria:

1. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.

2. Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance.

3. Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles per investigator's discretion.

4. Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases per investigator's discretion.

5. Pregnancy or nursing, as well as 3-6 months post-childbirth.

6. History of bleeding coagulopathies, or prolonged use of anticoagulants (daily aspirin dosing of 81 mg is acceptable).

7. Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medication per investigator's discretion.

8. Subjects with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regime.

9. Poorly controlled endocrine disorders, such as diabetes or thyroid abnormality per investigator's discretion.

10. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash per investigator's discretion.

11. History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin per investigator's discretion.

12. Any surgery in treated area within 3 months prior to treatment or before complete healing.

13. Injected fillers in the last 6 months and Botox in the last week.

14. Use of Isotretinoin (Accutane®) within 6 months prior to treatment.

15. As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the subject.

Related Conditions & MeSH terms

• Wrinkles

Intervention

Device:
• Silk'n HST
Treatment with Silk'n HST on the periorbital area as instructed in the user's manual

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Home Skinovations Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	reduction of wrinkle severity according to the Fitzpatrick wrinkle scale	measurements were accomplished via standardized photographs blinded evaluation.	18 weeks
Secondary	subjective wrinkle improvement as measured by satisfactory questionnaires	A subjective impression of improvement in wrinkle appearance following 6 weeks treatment, 3 months following treatment end.	18 weeks